Eric Bonnem is an Oncology physician affiliated with Translational Genomics Research Institute. OpenAlex indexes 41 publications with 1,274 citations (h-index 20).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
87 Mcgregor St
Dartmouth Hitchcock - Hematology/oncology
Manchester, NH 03102
Telephone
603-695-2500Registry record last updated 6 Jul 2018.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20241 payment
- Merck Sharp & Dohme LLCProgram year20231 payment
- Daiichi Sankyo Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.3%Aromatase Inhibitor18.7%Letrozole65%Anastrozole26%Exemestane9%Part D<11 patientsKinase inhibitor13.9%Jakafi31%Calquence27%Brukinsa13%Imatinib Mesylate10%Kisqali10%Tasigna9%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
13.1%Corticosteroid5.4%Prednisone100%Part D≥15 patientsPotassium supplement3.3%Potassium Chloride100%Part D≥11 patients+ 2 more classes in this area
Nervous system
12.3%Phenothiazine3.1%Prochlorperazine Maleate100%Part D≥19 patientsAntihistamine2.3%Hydroxyzine Hcl100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A phase Ib/II study of PXD101 alone and in combination with 5-fluorouracil in patients with advanced solid tumors
Journal of Clinical Oncology
2007 - Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinoma
Investigational New Drugs
1996 - Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans.
PubMed
1996 - A phase I trial of recombinant gamma interferon administered intravenously on a daily × 5 schedule
Journal of Oncology Pharmacy Practice
1996
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”